EP Patent

EP2654726A1 — Solid dispersion formulations and methods of use thereof

Assigned to Taro Pharmaceuticals Inc · Expires 2013-10-30 · 13y expired

What this patent protects

The present invention relates to formulations and methods for increasing the bioavailability of 1- (4-benzhydrylpiperazin-l-yl)-3,3-diphenylpropan-l-one, l-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceuticall…

USPTO Abstract

The present invention relates to formulations and methods for increasing the bioavailability of 1- (4-benzhydrylpiperazin-l-yl)-3,3-diphenylpropan-l-one, l-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.

Drugs covered by this patent

Patent Metadata

Patent number
EP2654726A1
Jurisdiction
EP
Classification
—
Expires
2013-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Taro Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.